Valuation
- Market cap
- 1,078,206,000
- Revenue TTM
- $36,880,000
- Net income TTM
- $-27,110,000
- PE ratio
- 0.00
- Forward PE
- —
- Profit margin
- -73.51%
- Debt to equity
- 0.00
Trading
- Volume
- 137,872
- Avg volume
- 155,046
- Day's range
- $21.45 – $24.51
- Shares out
- 50,620,000
- Stochastic %K
- 9%
- Beta
- 0.79
- Analysts
- Strong Sell
- Price target
- $64.00
Company profile
Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck, liver, prostate, pancreatic, esophageal, rectal, and non-small cell lung cancer. The...
Show more
Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck, liver, prostate, pancreatic, esophageal, rectal, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is based in Paris, France.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 33 1 40 26 04 70
- Website
- https://www.nanobiotix.com
- Address
- 60 rue de Wattignies, Paris, France
Latest news
No headlines yet.
